DWP 706
Alternative Names: DWP-706Latest Information Update: 26 Dec 2022
At a glance
- Originator Daewoong Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Corneal injuries
Most Recent Events
- 26 Dec 2022 DWP 706 is still in phase II trials for Corneal injuries (Ophthalmic, Drops) in South Korea (Daewoong pharmaceuticals pipeline; December 2022)
- 21 Oct 2020 Phase-II clinical trials in Corneal injuries in South Korea (Ophthalmic) (Daewoong Pharmaceutical pipeline, October 2020)
- 12 Jun 2020 Phase-I clinical trials in Corneal injuries in South Korea (Ophthalmic), prior to June 2020 (Daewoong Pharmaceutical pipeline, June 2020)